Study on the Safety and Effectiveness of Fianlimab and Cemiplimab Compared to Pembrolizumab in Treating Resectable Stage 3 or 4 Melanoma

Inclusion Criteria

• Have stage III (IIIB, IIIC, IIID) or stage IV (M1a, M1b, M1c) melanoma that can be completely removed by surgery.
• Have melanoma that is confirmed as cancerous by a pathology report.
• Be eligible for surgery with the goal of curing the cancer, and be able to have all cancer removed with clear margins.
• Undergo full disease staging with a physical exam and imaging tests, including CT scans and MRI, within 4 weeks before starting the study.
• Have an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.

Exclusion Criteria

• Have primary uveal melanoma.
• Have an autoimmune disease that required treatment with immunosuppressive drugs in the past 2 years, except for certain conditions like vitiligo or childhood asthma that has resolved.
• Have received any prior systemic anti-cancer therapy for melanoma, except for certain cases of prior radiotherapy.
• Have uncontrolled infections like HIV, hepatitis B, or hepatitis C, or an immunodeficiency that leads to chronic infection.
• Have used high doses of corticosteroids within 14 days before starting the study.
• Have been treated for other cancers in the past 5 years, except for certain cases.
• Have a history of myocarditis.
• Have a significant infection requiring antibiotics within 2 weeks before starting the study.